JohnHenryKregeMD

PubMed

• 2 citations
  Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
  Messoud Ashina, Caroline Roos, Lily Qian Li, Mika Komori, David Ayer, Dustin Ruff, John Henry Krege> ;Cephalalgia. 2023 Apr 1
• 6 citations
  Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.
  E Anne MacGregor, Mika Komori, John Henry Krege, Simin Baygani, Maurice Vincent, Jelena Pavlovic, Hisaka Igarashi> ;Cephalalgia. 2022 Dec 1
• 8 citations
  Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.
  John H Krege, Alicia W Gilsenan, John L Komacko, Nicole Kellier-Steele> ;JBMR Plus. 2022 Sep 1
• 2 citations
  The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Second...
  Erin G Doty, Paula M Hauck, John H Krege, Mika Komori, Ann M Hake, Yan Dong, Richard B Lipton> ;CNS Drugs. 2022 Jul 1
• 5 citations
  Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis.
  John H Krege, Simin K Baygani, Mika Komori, Sinéad M Ryan, Maurice Vincent, Lipton, R.> ;Pain and Therapy. 2022 Jun 1
• 11 citations
  Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine.
  Cristina Tassorelli, Sonja M. Bragg, John H. Krege, Erin G Doty, P A Ardayfio, Dustin D. Ruff, Sherie A. Dowsett, Todd J. Schwedt> ;The Journal of Headache and Pain. 2021 Nov 6
• 6 citations
  Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
  Uwe Reuter, John H. Krege, Louise Lombard, Elisa Gomez Valderas, Judith Krikke-Workel, Grazia Dell'Agnello, Sherie A. Dowsett, Dawn C. Buse> ;Cephalalgia. 2021 Oct 13
• 3 citations
  A close association of freedom from pain, migraine-related functional disability, and other outcomes: Results of a post hoc analysis of randomized lasmiditan studies S...
  Simin K. Baygani, Stewart J. Tepper, John H. Krege, Raghavendra Vasudeva, Eric M. Pearlman, Paula M. Hauck, Li Shen Loo, Richard B. Lipton> ;The Journal of Headache and Pain. 2021 Aug 28
• 33 citations
  Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
  Messoud Ashina, Uwe Reuter, Timothy Smith, Judith Krikke-Workel, Suzanne Klise, Sonja M. Bragg, Erin G Doty, Sherie A. Dowsett, Qun Lin, John H. Krege> ;Cephalalgia. 2021 Feb 4
• 10 citations
  Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
  Stewart J. Tepper, Raghavendra Vasudeva, John H. Krege, S. Rathmann, Erin G Doty, Bert B. Vargas, Delphine Magis, Mika Komori> ;Headache. 2020 Sep 1
• 7 citations
  Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant.
  Erin G Doty, John H. Krege, Gerhardt Pohl, Michael Case, Sherie A. Dowsett, Stewart J. Tepper> ;Headache. 2020 Sep 1
• 8 citations
  Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
  Timothy Smith, John H. Krege, S. Rathmann, Sherie A. Dowsett, Ann Marie Hake, Emel Serap Monkul Nery, Brandy R. Matthews, Erin G Doty> ;Neurology and Therapy. 2020 May 23
• 29 citations
  Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
  Louise Lombard, Dustin D. Ruff, John H. Krege, Li Shen Loo, Andrew S. Buchanan, Thomas E. Melby, Dawn C. Buse, Richard B. Lipton> ;The Journal of Headache and Pain. 2020 Feb 24
• 11 citations
  Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan.
  David Kudrow, John H. Krege, Hans Peter Hundemer, Paul Berg, Rashna Khanna, Michael H. Ossipov, Patricia Pozo-Rosich> ;Headache. 2020 Jan 13
• 31 citations
  Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
  Kerry Knievel, Andrew S. Buchanan, Louise Lombard, Simin K. Baygani, Joel Raskin, John H. Krege, Li Shen Loo, Mika Komori, Joshua Tobin> ;Cephalalgia. 2020 Jan 1
• 53 citations
  Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIAT...
  Jan Lewis Brandes, Suzanne Klise, John H. Krege, Michael Case, Rashna Khanna, Raghavendra Vasudeva, Joel Raskin, Eric M. Pearlman, David Kudrow> ;Cephalalgia. 2019 Aug 21
• 22 citations
  Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
  Li Shen Loo, Brian M. Plato, Ira M. Turner, Michael Case, Joel Raskin, Sherie A. Dowsett, John H. Krege> ;BMC Neurology. 2019 Aug 13
• 29 citations
  Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
  Li Shen Loo, Jessica Ailani, Jack Schim, Simin K. Baygani, Hans-Peter Hundemer, Martha Port, John H. Krege> ;The Journal of Headache and Pain. 2019 Jul 24
• 17 citations
  Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
  Erin G Doty, John H. Krege, Leah Jin, Joel Raskin, Rashmi B. Halker Singh, Kavita Kalidas> ;Cephalalgia. 2019 Jul 3
• 20 citations
  Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.
  Stewart J. Tepper, John H. Krege, Louise Lombard, Josephine K. Asafu-Adjei, Sherie A. Dowsett, Joel Raskin, Andrew S. Buchanan, Deborah I. Friedman> ;Headache. 2019 Jul 1
• 48 citations
  Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN:
  John H. Krege, Paul Rizzoli, Emily Liffick, Erin G Doty, Sherie A. Dowsett, Jianing Wang, Andrew S. Buchanan> ;Cephalalgia. 2019 Jun 5
• 61 citations
  Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis.
  Adolfo Diez-Perez, Fernando Marin, Erik Fink Eriksen, David L. Kendler, John H. Krege, Miguel Delgado-Rodríguez> ;Bone. 2019 Mar 1
• 14 citations
  Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.
  Stuart L. Silverman, Bente L. Langdahl, Saeko Fujiwara, Kenneth G. Saag, Nicola Napoli, Satoshi Soen, Hiroyuki Enomoto, Thomas E. Melby, Damon Disch, Fernando Marin, J...> ;Calcified Tissue International. 2019 Feb 1
• 9 citations
  Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Asse...
  Eleftherios P. Paschalis, John H. Krege, Sonja Gamsjaeger, Erik Fink Eriksen, David B. Burr, Damon Disch, Jan J. Stepan, Astrid Fahrleitner-Pammer, Klaus Klaushofer, F...> ;Journal of Bone and Mineral Research. 2018 Sep 14
• 48 citations
  Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 ...
  Bente L. Langdahl, Stuart L. Silverman, Saeko Fujiwara, Kenneth G. Saag, Nicola Napoli, Satoshi Soen, Hiroyuki Enomoto, Thomas E. Melby, Damon Disch, Fernando Marin, J...> ;Bone. 2018 Nov 1
• Join now to see all

Journal Articles

• Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene  
  Cosman F, Keaveny T.M., Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH, JBMR, 1/1/2013
• Fractures in Women Treated with Raloxifene or Alendronate: A Retrospective Database Analysis  
  Foster SA, Shi N, Curkendall S, Stock J, Chu B, Burge R, Diakun D, Krege JH, BMC Women's Health, 1/1/2013
• Changes in Vitamin D Metabolites during Teriparatide Treatment  
  Cosman F, Dawson-Hughes B, Wan X, Krege JH, Bone, 1/1/2012
• National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges  
  Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall S, Osteoporos Int, 1/1/2012
• Teriparatide and the Risk of Nonvertebral Fractures in Women with Postmenopausal Osteoporosis  
  Krege JH, Wan X, Bone, 1/1/2012
• Effect of Teriparatide Compared with Risedronate on Reduction of Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures  
  Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL, Osteoporos Int, 1/1/2012
• Long-term raloxifene for postmenopausal osteoporosis  
  Recker RR, Mitlak BM, Ni X, Krege JH, Curr Med Res Opinion, 1/1/2011
• Effects of Raloxifene and Alendronate on Bone Turnover as Assessed by Procollagen Type I N-Propeptide  
  Eastell R, Ni X, Rogers A, Krege JH, Osteoporosis International, 1/1/2011
• Benefits and risks of raloxifene in women with osteoporosis and no previous fracture  
  Sontag A, Wan X, Krege JH, Current Medical Research and Opinion, 1/1/2010
• First Fractures Among Postmenopausal Women with Osteoporosis  
  Sontag A, Krege JH, Journal of Bone and Mineral Metabolism, 1/1/2010
• Vertebral Fracture Status and the World Health Organization (WHO) Risk Factors for Predicting Osteoporotic Fracture Risk  
  Chen P, Krege JH, Goltzman D, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos M., Kreiger N, Olszynski WP, Josse RG, Adachi JD, and The CaMos Research Group, Journal of Bone and Mineral Research, 1/1/2009
• Effects of Teriparatide versus Alendronate for Treating Glucocorticoid-induced Osteoporosis: 36-month Results  
  Saag KG, Zanchetta JR, Devogelaer J-P, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR, Arthritis and Rheumatism, 1/1/2009
• Teriparatide Vertebral Fracture Risk Reduction Determined by Quantitative and Qualitative Radiographic Assessment  
  Prevrhal S., Krege JH, Chen P., Genant H, Black D, Current Medical Research and Opinion, 1/1/2009
• Effects of Arzoxifene on Bone Mineral Density and Endometrium in Postmenopausal Women with Normal or Low Bone Mass  
  Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL, Alam J, Lakshmanan M, Omizo M, Journal of Clinical Endocrinology and Metabolism, 1/1/2009
• Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent  
  Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH, Journal of Clinical Endocrinology and Metabolism, 1/1/2009
• Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis  
  Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH, Osteoporosis International, 1/1/2009
• Measuring serum calcium before and after teriparatide treatment: authors' response  
  Wermers RA, Cosman F, Recknor CP, Xie L, Glass EV, Krege JH, Osteoporosis International, 1/1/2008
• Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate  
  Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH, Osteoporosis International, 1/1/2008
• Teriparatide in Postmenopausal Women with Osteoporosis and Impaired Renal Function  
  Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH, Osteoporosis International, 1/1/2007
• Osteosarcoma and teriparatide? [letter, essentially same as letter in CMRO in number 40]  
  Harper KD, Krege JH, Marcus R, Mitlak BH, Journal of Bone and Mineral Research, 1/1/2007
• Response to Teriparatide in Patients with Baseline 25-Hydroxyvitamin D Insufficiency or Sufficiency  
  Dawson-Hughes B, Chen P, Krege JH, Journal of Clinical Endocrinology and Metabolism, 1/1/2007
• Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide  
  Miller PD; Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R, Journal of Clinical Endocrinology and Metabolism, 1/1/2007
• Reply by Boonen et Al [letter]  
  Boonen S. Marin F. Krege JH. Rosen CJ, Journal of the American Geriatrics Society, 1/1/2006
• Development of an algorithm for using PINP to monitor treatment of patients with teriparatide  
  Eastell R, Krege JH, Chen P, Glass EV, Reginster JY, Current Medical Research & Opinion, 1/1/2006
• Comments on initial experience with teriparatide in the United States [letter]  
  Harper KD, Krege JH, Marcus R, Mitlak BH, Current Medical Research and Opinion, 1/1/2006
• Join now to see all

Books/Book Chapters

• Molecular Genetics of Hypertension. 
  Chapter: Mutating genes to study hypertension. 
  Krege JHEditors: Dominiczak AF, Connell JMC, and Soubrier F.Bios Scientific Publishers, Oxford1999
• OECD Proceedings: Novel Systems for the Study of Human Disease. Europe: Organisation for Economic Co-operation and Development 
  Chapter: An experiment-based classification of blood pressure genes. 
  Krege JH1998
• Molecular Genetics and Gene Therapy of Cardiovascular Diseases. 
  Chapter: Using animal models to dissect complex traits. 
  Page 271 - 292Krege JH, Kurtz TW, Smithies OEditors: Mockrin SC.Marcel Dekker, Inc., New York, NY1996

Abstracts/Posters

• Effect of teriparatide in patients with osteoporosis with prior vertebral fracture.
  Valenzuela G, Yim D, Beall DP, Gordon M, Krege JH, Krohn K., ACR, 1/1/2014
• Relationship of spine fracture burden to reduced lung volume in postmenopausal women with osteoporosis.
  Krege JH, Kendler D, Krohn K, Genant H, Berclaz P-Y, Loghin C, ASBMR, 1/1/2014
• Very early responses of biochemical markers of bone turnover to teriparatide.
  Robins DA, Leder BZ, Krohn KD, Alam J, Murphy HL, Chiang AY, Krege JH, ASBMR, 1/1/2014
• Effect of teriparatide in patients with osteoporosis and type 2 diabetes mellitus.
  Schwartz A, Krege JH, Alam J, Schuster D, ASBMR, 1/1/2014
• Effect of prior hip fracture status in patients with osteoporosis receiving teriparatide.
  Krohn L, Valenzuela G, Lane JM, Gruber B, Alam J, Chiang AY, Krege JH, Osteoporos Int, 1/1/2014
• Hip and Spine Strength Effects of Adding Versus Switching to Teriparatide in Postmenopausal Women with Osteoporosis Treated with Prior Alendronate or Raloxifene.
  Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH, ASBMR, 1/1/2012
• Unmet Need for Osteoporosis Treatment in Real World Hip Fracture Patients.
  Johnston SS, Zhao Y, McMorrow D, Krege JH, Krohn K, ASBMR, 1/1/2012
• Genetic variants in GPR177 and LRP5 may be associated with risk of lumbar spine fracture.
  O’Brien LA, Ouyang H, Krege JH, Kohler JR, ASBMR, 1/1/2012
• Unmet Need for Osteoporosis Treatment in Real World Kyphoplasty/Vertebroplasty Patients.
  Zhao Y, Johnston SS, McMorrow D, Krohn K, Krege JH, ASBMR, 1/1/2012
• Association between teriparatide adherence and healthcare utilization and costs in real world U.S. hip fracture patients.
  Johnston SS, Zhao Y, Smith DM, McMorrow D, Krohn K, Krege JH, ISPOR, 1/1/2012
• Association between teriparatide adherence and healthcare utilization and costs in real world U.S. kyphoplasty/vertebroplasty patients.
  Zhao Y, Johnston SS, Smith DM, McMorrow D, Krege JH, Krohn K, ISPOR, 1/1/2012
• Age, Bone Mineral Density, and Spine Fracture Status for Predicting Fracture Risk.
  Krege JH, Wan X, Lentle B, Berger C, Langsetmo L, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Krieger N, Olszynski WP, Josse RG, Goltzman D and the CaMos Research Group, ASBMR, 1/1/2011
• The 3/2 Power of Bone Mineral Apparent Density.
  Wan X, Krege JH, ASBMR, 1/1/2011
• Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures.
  Hadji P, Zanchetta JR, Russo LA, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan ML, Masica DN, Mitlak BH, Stock JL, ECTS, 1/1/2011
• Algorithm for Using a Bone Formation Marker PINP to Monitor the Response to Teriparatide (TPTD) in Patients with Glucocorticoid-Induced Osteoporosis (GIO).
  Lane NE, See K, Warner MR, Krege JH, Arthritis and Rheumatism, 1/1/2010
• Effects of Raloxifene and Alendronate on Bone Turnover as Assessed by Procollagen Type I N-Propeptide (PINP).
  Eastell R, Rogers A, Ni X, Krege JH, ECTS, 1/1/2010
• Fractures in Commercial and Medicare Patients Treated with Raloxifene or Alendronate: A Retrospective Database Analysis.
  Foster SA, Curkendall S, Shi N, Stock JL, Chu B-C, Burge R, Diakun D, Krege JH, JBMR, 1/1/2010
• Teriparatide and Risk of Nonvertebral Fractures in Women with Postmenopausal Osteoporosis.
  Krege JH, Wan X, JBMR, 1/1/2010
• Relationship Between Body Composition and the Skeleton.
  Wan X, Krege JH, Jiang Y, JBMR, 1/1/2010
• PCN31 A descriptive analysis of the association between breast cancer risk, bonem mineral density, and fractures in postmenopausal women in the Canadian Multicenter Os...
  Ioannidis G, Adachi J, Burge RT, Papadimitropoulos M, Krege JH, Stock JL, Muram D, Value in Health, 1/1/2009
• Prevention of osteoporosis in postmenopausal women with normal or low bone mass treated with arzoxifene.
  Broy S, Krege JH, Bolognese M, Utian WH, Alam J, Glass EV, Stock JL, Omizo M, Am Soc Bone Miner Res, 1/1/2009
• Serum osteocalcin concentrations in patients with glucocorticoid-induced osteoporosis treated with alendronate or teriparatide.
  Eastell R, Chen P, Saag KG, Burshell AL, Warner MR, Dalsky GP, Krege JH, Bone, 1/1/2009
• Serum osteocalcin concentrations in patients with glucocorticoid-induced osteoporosis treated with alendronate or teriparatide.
  Eastell R, Chen P, Saag KG, Burshell AL, Warner MR, Dalsky GP, Krege JH, Calcif Tissue Int, 1/1/2009
• Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results.
  Devogelaer JP, Saag KG, Zanchetta JR, Adler R, Eastell R, See K, Dalsky GP, Krohn K, Krege JH, Warner MR, ECCEO Annual Meeting, 1/1/2009
• Arzoxifene in postmenopausal women with normal or low bone mass.
  Utian W, Krege JH, Bolognese M, Feldman R, Broy S, Meats D, Alam J, Lakshmanan M, Omizo M, Maturitas, 1/1/2009
• Join now to see all

Lectures

• Assessing Fracture Risk 
  Indianapolis, IN - 1/1/2010
• Introduced and presented new slide decks. 
  San Diego, CA; Atlanta, GA - 1/1/2010
• New Evista Bone Deck 
  1/1/2009
• Assessing absolute fracture risk. 
  Budapest, Hungary - 1/1/2009
• Principles of post-hoc research. 
  Carmel, CA - 1/1/2009
• Drug and protocol overviews. 
  Miami, FL; Berlin, Buenos Aires, Argentina; Sidney, Australia - 1/1/2007
• Preos-Forteo Comparison 
  Indianapolis, IN - 1/1/2006
• Teriparatide Inhalation Powder Clinical Development Plan 
  Indianapolis, IN - 1/1/2006
• Teriparatide safety. 
  Philadelphia, PA - 1/1/2006
• Potential new Forteo application. 
  1/1/2005
• Back pain data. 
  Barcelona, Spain - 1/1/2005
• Overview of osteoporosis and therapies. 
  Indianapolis, IN - 1/1/2005
• Preos Competitive Workshop 
  Indianapolis, IN - 1/1/2005
• Combination anabolic plus antiresorptive therapy. 
  Rome, Italy - 1/1/2005
• Evista and bone quality. 
  Indianapolis, IN - 1/1/2004
• Forteo data. 
  New York, NY - 1/1/2004
• PINP and Forteo data. 
  Scottsdale, AZ - 1/1/2004
• Forteo dental applications, quantitative morphometry, and radiograph initiative. 
  1/1/2003
• Forteo effects on bone quality. 
  1/1/2003
• Evista Data 
  Beaver Creek, CO - 1/1/2003
• Recruitment 
  Chicago, IL - 1/1/2003
• Forteo new data. 
  Florence, Italy - 1/1/2003
• Forteo data 
  Frankfurt, Germany - 1/1/2003
• Forteo overview. 
  Gothenburg - 1/1/2003
• X in window problem. 
  Indianapolis, IN - 1/1/2003
• Join now to see all